通过mRNA封装的脂质纳米颗粒进行增强的表观遗传调制,可实现针对性的抗炎控制
Tahere Mokhtari1,2,3, Mohammad N Taheri1,2,3, Sarah Akhlaghi1,2
1Division of Experimental Pathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
bioRxiv : the preprint server for biology
|March 10, 2025
概括
这项研究介绍了一种由脂质纳米颗粒传递的新指抑制系统,用于控制体内免疫反应. 这项技术在治疗败血症和通过调节炎症通路来改善基因疗法方面表现有前途.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 基因治疗 基因治疗
背景情况:
- 免疫基因表达的时间控制对于治疗炎症性疾病至关重要.
- 现有的免疫调节策略在精度和安全性方面存在局限性.
研究的目的:
- 开发和评估一种基于指 (ZF) 的增强型转录抑制系统,用于体内免疫调节.
- 评估针对炎症性疾病的Myd88的治疗潜力,并改善基因疗法交付.
主要方法:
- 基于ZF的工程转录抑制器.
- 通过脂质纳米粒子 (LNP) 传递.
- 准Myd88,一个关键的免疫适应分子.
- 在C57BL / 6J小鼠体内研究,包括败血症和重复的腺相关病毒 (AAV) 管理模型.
主要成果:
- 已证明对败血症的治疗疗效.
- 成功降低了抗体反应,改善了重复的AAV给药.
- 展示了免疫信号通路的体内控制.
结论:
- 增强的ZF抑制系统为安全有效的免疫调节提供了一个新的平台.
- 通过这种系统的表观遗传工程对于涉及不平衡炎症反应的疾病具有广泛的适用性.
- 这种方法有可能在免疫学和基因治疗中推进治疗策略.
相关概念视频
Experimental RNAi
6.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.0K
Inflammatory Bowel Disease IV: Pharmacological Management
86
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
86
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107


